About GH Research PLC
https://www.ghres.comGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
CEO
Velichka Valcheva
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BVF INC/IL
Shares:8.83M
Value:$149.28M
LYNX1 CAPITAL MANAGEMENT LP
Shares:8.6M
Value:$145.45M
RA CAPITAL MANAGEMENT, L.P.
Shares:7.68M
Value:$129.81M
Summary
Showing Top 3 of 52
About GH Research PLC
https://www.ghres.comGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $16.45M ▲ | $-14.02M ▼ | 0% | $-0.23 ▼ | $-13.91M ▼ |
| Q2-2025 | $0 | $14.7M ▲ | $-9.29M ▲ | 0% | $-0.15 ▲ | $-9.2M ▲ |
| Q1-2025 | $0 | $12.73M ▼ | $-10.81M ▼ | 0% | $-0.19 ▼ | $-10.73M ▼ |
| Q4-2024 | $0 | $12.94M ▲ | $-8.8M ▲ | 0% | $-0.17 ▲ | $-8.71M ▲ |
| Q3-2024 | $0 | $12.62M | $-12.11M | 0% | $-0.23 | $-12.02M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $288.51M ▼ | $302.02M ▼ | $10.63M ▲ | $291.4M ▼ |
| Q2-2025 | $291.54M ▲ | $313.43M ▼ | $10.25M ▲ | $303.18M ▼ |
| Q1-2025 | $291.35M ▲ | $320.45M ▲ | $10.24M ▲ | $310.21M ▲ |
| Q4-2024 | $149.32M ▼ | $188.27M ▼ | $9.32M ▼ | $178.95M ▼ |
| Q3-2024 | $150.04M | $199.61M | $10.24M | $189.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.02M ▼ | $-14.44M ▼ | $10.44M ▼ | $968.65K ▲ | $-4.22M ▼ | $-14.48M ▼ |
| Q2-2025 | $-9.29M ▲ | $-8.97M ▼ | $15.71M ▲ | $-1.07M ▼ | $8.92M ▼ | $-9.03M ▼ |
| Q1-2025 | $-10.81M ▼ | $-8.57M ▲ | $11.84M ▼ | $140.86M ▲ | $144.16M ▲ | $-8.58M ▲ |
| Q4-2024 | $-8.8M ▲ | $-10.45M ▲ | $21.33M ▲ | $-59K ▲ | $10.73M ▲ | $-10.47M ▲ |
| Q3-2024 | $-12.11M | $-12.31M | $15.28M | $-60K | $2.93M | $-12.31M |
CEO
Velichka Valcheva
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BVF INC/IL
Shares:8.83M
Value:$149.28M
LYNX1 CAPITAL MANAGEMENT LP
Shares:8.6M
Value:$145.45M
RA CAPITAL MANAGEMENT, L.P.
Shares:7.68M
Value:$129.81M
Summary
Showing Top 3 of 52